Company Overview - Nexxen International Ltd. is a global advertising technology platform specializing in data and advanced TV [3][4] - The company operates a flexible and unified technology stack that includes a demand-side platform (DSP) and supply-side platform (SSP), centered around the Nexxen Data Platform [3] Recent Announcements - Nexxen announced participation in financial conferences, including a fireside chat at the Canaccord Genuity Annual Growth Conference on August 13 and a virtual fireside chat at the Rosenblatt Annual Technology Summit on August 19 [1][5] - Live webcasts of these events will be available on Nexxen's investor relations website, with replays accessible for approximately one year [1] Global Presence - The company is headquartered in Israel and has offices across the United States, Canada, Europe, and Asia-Pacific [4]

Core Insights - Inspired Entertainment, Inc. reported strong financial results for the quarter ended June 30, 2025, with total revenue of $80.3 million, representing a 7% increase year-over-year, primarily driven by record Interactive revenue growth of 45% [8][10][9] Financial Performance - Total revenue for the quarter was $80.3 million, up from $74.8 million in the prior year, with Interactive revenue increasing to $13.6 million from $9.4 million [10][8] - Adjusted EBITDA reached $28.4 million, a 15% increase from $24.7 million in the previous year, with Interactive Adjusted EBITDA growing by 49% year-over-year [8][10] - The company reported a net loss of $7.8 million, compared to a net income of $1.4 million in the same quarter last year [10][8] Segment Performance - The Interactive segment was a key growth driver, with revenue increasing by 45% year-over-year, supported by strong performance in North America and the UK [2][9] - Gaming segment Adjusted EBITDA increased by 35% year-over-year, driven by the successful rollout of Vantage cabinets with William Hill [3][10] - Virtual Sports segment saw sequential growth in revenue and Adjusted EBITDA, with localized content in Brazil showing early promise [4][10] Strategic Developments - The company secured a five-year partnership with Jenningsbet to supply approximately 570 Vantage terminals, enhancing its market presence [8][13] - A comprehensive debt refinancing was completed, issuing £270 million in senior secured notes and securing a new £17.8 million revolving credit facility [8][9] Operational Highlights - The Interactive segment's Adjusted EBITDA margin expanded to 67%, reflecting the scalability of digital operations [2][10] - The Leisure segment performed steadily, with year-to-date revenue up 5% and Adjusted EBITDA up 19% compared to the same period last year [5][10]

LAS VEGAS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI) a leader in propulsion-agnostic bus and coach mobility solutions, subsidiary Alexander Dennis, today celebrated the official opening of its U.S. manufacturing facility in Las Vegas. To commemorate the facilities launch it handed over the first two of 10 new Enviro500 double deck buses to the Regional Transportation Commission of Southern Nevada (RTC). The opening of the new manufacturing facility is a signi ...

NOT FOR RELEASE TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that it has completed its initial public offering on the Australian Securities Exchange (“ASX”) consisting of the issuance of 65,789,474 CHESS Depository Interests (“CDIs”) over fully paid common shares in the capital of the Company ("Shares") at an offer price of A ...

Core Viewpoint - First Quantum Minerals Ltd. has initiated a cash tender offer to purchase all outstanding 6.875% Senior Notes due 2027 as part of a refinancing strategy [1][6]. Tender Offer Details - The tender offer will expire on August 12, 2025, at 5:00 PM New York City time [2]. - Holders of the notes will receive a cash amount based on a fixed spread plus the yield of a U.S. Treasury Reference Security, along with accrued interest [2][6]. - Notes can be withdrawn at any time before the expiration date, and accepted notes will be canceled upon completion of the tender offer [3]. Purpose and Financing - The tender offer aims to acquire all outstanding notes as part of a refinancing transaction, with plans to issue new senior notes [6]. - Proceeds from the new notes issuance are expected to fund the purchase of the tendered notes and redeem any notes not tendered [6][10]. - The company intends to redeem any notes not validly tendered after October 15, 2025, at a redemption price of 100% plus accrued interest [7][10]. Conditions and Amendments - The completion of the tender offer is subject to the successful issuance of new notes and satisfaction of financing conditions [10]. - The company reserves the right to amend or waive conditions of the tender offer, extend the expiration date, or modify the terms [11][10]. Additional Information - The company has engaged several financial institutions as dealer managers for the tender offer [13]. - Full details regarding the tender offer can be obtained from the company's Offer to Purchase [12].

Core Insights - Arch Biopartners Inc. has initiated dosing in its Phase II trial for LSALT peptide aimed at preventing cardiac surgery-associated acute kidney injury (CS-AKI) with the first patient successfully dosed at Toronto General Hospital [1][9] - The trial is a multi-center, randomized, double-blind, placebo-controlled study targeting 240 patients, with the primary objective to evaluate the incidence of acute kidney injury within seven days post cardiac surgery [4][12] - The company is expanding its clinical trial sites in Canada and the United States, with St. Michael's Hospital expected to be the next site activated [3][9] Company Overview - Arch Biopartners is focused on developing drugs targeting the dipeptidase-1 (DPEP1) pathway to prevent organ damage caused by inflammation, particularly in the kidneys, lungs, and liver [14][10] - LSALT peptide is the lead drug candidate, which has shown a strong safety profile in previous trials and aims to address the significant unmet medical need for therapies preventing CS-AKI [13][10] Trial Details - The ongoing Phase II trial involves a dosing regimen of 10mg of LSALT peptide administered intravenously twice daily for five days, with subjects randomized to receive either the peptide or a placebo [4][10] - The trial's completion is estimated for August 2026, reflecting the time required for Canadian sites to prepare and obtain necessary approvals [6] Clinical Significance - CS-AKI is a common complication in cardiac surgery, affecting up to 30% of patients undergoing on-pump procedures, leading to serious health risks and increased mortality [12][8] - The LSALT peptide represents a potential first-in-class therapeutic approach to mitigate inflammation injury in this high-risk patient population [13][10]

Core Insights - Kornit Digital Ltd. reported second quarter results for 2025, achieving revenues of $49.8 million, which aligns with previous guidance and shows a slight increase from $48.6 million in the same period last year [7][8] - The company experienced a GAAP net loss of $7.5 million, compared to a net loss of $4.9 million in the second quarter of 2024, while non-GAAP net income was $1.2 million, slightly up from $1.1 million year-over-year [7][8] - Kornit Digital is focusing on scaling the adoption of its Apollo and AIC systems, expanding its customer base in screen printing, and maintaining profitability in adjusted EBITDA and operating cash flow [3][4] Financial Performance - Second quarter revenues were $49.8 million, up from $48.6 million year-over-year [8] - GAAP gross profit margin decreased to 41.7% from 45.8% in the prior year, while non-GAAP gross profit margin fell to 46.3% from 48.6% [8] - GAAP operating expenses were $31.6 million, down from $33.0 million in the prior year, with non-GAAP operating expenses decreasing by 4.4% to $26.7 million [8] - Adjusted EBITDA loss for the second quarter was $1.2 million, an improvement from a loss of $1.6 million in the same quarter of 2024, resulting in an adjusted EBITDA margin of negative 2.3% compared to negative 3.4% [8][34] Future Guidance - For the third quarter of 2025, Kornit Digital expects revenues to be in the range of $49 million to $55 million, with an adjusted EBITDA margin projected between negative 3% and 3% [5] Business Strategy - The company is focused on transforming its business model towards recurring revenue and long-term growth, despite a modest outlook for the second half of the year [2][3] - Kornit Digital is seeing positive traction from screen-printing customers adopting digital solutions for the first time and from customized design customers expanding their capacity [2][3]

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal second quarter ended June 28, 2025. Highlights 2Q 2025 revenues of $762.3 millionGross margin was 19.5% and included the negative impact of approximately 160 basis points related to the addition of Newport2Q 2025 EPS of $0.012Q 2025 Adjusted loss per share of $(0.07)2Q 2025 boo ...

MiniLuxe wins the annual Boston Magazine, Best of Boston Award for Best Mani and PediBoston, MA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MiniLuxe, a leader in clean beauty and self-care services, proudly announces receiving Best Manicure and Pedicure Services granted by Boston Magazine’s Best of Boston 2025. Meticulously researched by the magazine’s writers and editors who spend months testing and debating, Boston Magazine’s list of winners represents “Boston’s must-visit list this year.” MiniLuxe has won the aw ...

Core Viewpoint - MannKind Corporation has entered into a strategic financing agreement with Blackstone, providing up to $500 million in non-dilutive capital to support its growth strategies and commercial initiatives [1][2]. Group 1: Financing Details - MannKind will receive an initial $75 million in cash at closing, with a total financing facility of up to $500 million [1]. - The financing includes a $125 million delayed draw term loan (DDTL) available over the next 24 months, and an additional $300 million uncommitted DDTL subject to mutual consent [2]. - The facility bears interest at a SOFR variable rate plus 4.75%, with potential increases based on leverage ratios, and matures in August 2030 without scheduled amortization payments [2]. Group 2: Strategic Implications - The funding will enhance MannKind's operational flexibility and support the expansion of its commercial team in anticipation of the pediatric indication for Afrezza, pending approval [2]. - The capital will also facilitate continued pipeline advancement and potential business development opportunities [2]. - Blackstone's involvement is expected to provide MannKind with access to a value creation platform and life sciences expertise, aiding in commercialization efforts [2]. Group 3: Company Overview - MannKind Corporation focuses on developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases [3]. - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices [4].